Drugs / DFP-14927
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03943004 | Sep 2019 → Mar 2026 overdue | cancer | Delta-Fly Pharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFP-14927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03943004 ↗ |
| Known as | DFP-10917 | “DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.” NCT03943004 ↗ |
| Route | Intravenous | “DFP-14927 intravenous infusion administered” NCT03943004 ↗ |